Respiratory syncytial virus infection and the immunocompromised host

P. L. Ogra, Janak Patel

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Clearly the use of ribavirin and possibly of ISG represents a small but significant revolution in the treatment of RSV infection in the compromised host. It is inevitable that new and more effective treatment modalities will emerge. Whether the current therapeutic approach with ribavirin alone or in combination with ISG is truly 'life-saving' in severe RSV disease, however, remains to be determined. Until additional information becomes available ribavirin as well as ISG deserve the benefit of doubt for continued use in carefully selected and properly monitored patients with severe RSV disease.

Original languageEnglish (US)
Pages (from-to)246-249
Number of pages4
JournalPediatric Infectious Disease Journal
Volume7
Issue number4
StatePublished - 1988
Externally publishedYes

Fingerprint

Respiratory Syncytial Virus Infections
Ribavirin
Immunocompromised Host
Therapeutics
Infection

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pediatrics, Perinatology, and Child Health

Cite this

Respiratory syncytial virus infection and the immunocompromised host. / Ogra, P. L.; Patel, Janak.

In: Pediatric Infectious Disease Journal, Vol. 7, No. 4, 1988, p. 246-249.

Research output: Contribution to journalArticle

Ogra, P. L. ; Patel, Janak. / Respiratory syncytial virus infection and the immunocompromised host. In: Pediatric Infectious Disease Journal. 1988 ; Vol. 7, No. 4. pp. 246-249.
@article{07100a82b94d42d2a5699a3f58670e08,
title = "Respiratory syncytial virus infection and the immunocompromised host",
abstract = "Clearly the use of ribavirin and possibly of ISG represents a small but significant revolution in the treatment of RSV infection in the compromised host. It is inevitable that new and more effective treatment modalities will emerge. Whether the current therapeutic approach with ribavirin alone or in combination with ISG is truly 'life-saving' in severe RSV disease, however, remains to be determined. Until additional information becomes available ribavirin as well as ISG deserve the benefit of doubt for continued use in carefully selected and properly monitored patients with severe RSV disease.",
author = "Ogra, {P. L.} and Janak Patel",
year = "1988",
language = "English (US)",
volume = "7",
pages = "246--249",
journal = "Pediatric Infectious Disease Journal",
issn = "0891-3668",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Respiratory syncytial virus infection and the immunocompromised host

AU - Ogra, P. L.

AU - Patel, Janak

PY - 1988

Y1 - 1988

N2 - Clearly the use of ribavirin and possibly of ISG represents a small but significant revolution in the treatment of RSV infection in the compromised host. It is inevitable that new and more effective treatment modalities will emerge. Whether the current therapeutic approach with ribavirin alone or in combination with ISG is truly 'life-saving' in severe RSV disease, however, remains to be determined. Until additional information becomes available ribavirin as well as ISG deserve the benefit of doubt for continued use in carefully selected and properly monitored patients with severe RSV disease.

AB - Clearly the use of ribavirin and possibly of ISG represents a small but significant revolution in the treatment of RSV infection in the compromised host. It is inevitable that new and more effective treatment modalities will emerge. Whether the current therapeutic approach with ribavirin alone or in combination with ISG is truly 'life-saving' in severe RSV disease, however, remains to be determined. Until additional information becomes available ribavirin as well as ISG deserve the benefit of doubt for continued use in carefully selected and properly monitored patients with severe RSV disease.

UR - http://www.scopus.com/inward/record.url?scp=0023945310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023945310&partnerID=8YFLogxK

M3 - Article

C2 - 3368256

AN - SCOPUS:0023945310

VL - 7

SP - 246

EP - 249

JO - Pediatric Infectious Disease Journal

JF - Pediatric Infectious Disease Journal

SN - 0891-3668

IS - 4

ER -